null

SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O

InChI Key InChIKey=IRBVGTPPFBYDKX-UHFFFAOYSA-N

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 24 hits for monomerid = 230107   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2BK1B6SUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2SF2Z7QUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2SF2Z7QUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.480nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q27S7R2CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.330nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q27S7R2CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q27S7R2CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q27S7R2CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2C53P6VUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2C53P6VUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 1nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in anti-IgM/IgG-induced CD86 surface expressionMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in CD40/CD40L-induced CD86 surface expressionMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Inhibition of BTK in human PBMC cells assessed as inhibition of FCepsilonR1/immune complex-induced TNFalpha productionMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Mus musculus)TBA
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 130nMAssay Description:Inhibition of BTK in mouse whole blood assessed as reduction in anti-IgM/IgG-induced CD69 surface expression on peripheral B cellsMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 54nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in FCepsilonR1/anti-IgE-induced CD63 surface expression on basophilsMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 0.550nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 300nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 87nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb Company

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)copy SMILEScopy InChI
Affinity DataIC50: 162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2PN9966PubMed